First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

• Main Authors: Cesar Miranda-Verastegui (Author), Gianfranco Tulliano (Author), Theresa W Gyorkos (Author), Wessmark Calderon (Author), Elham Rahme (Author), Brian Ward (Author), Maria Cruz (Author), Alejandro Llanos-Cuentas (Author), Greg Matlashewski (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2009-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<h4>Background</h4>Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective t...